DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Adcetris (Brentuximab Vedotin) - Indications and Dosage

 
 



INDICATIONS AND USAGE

Hodgkin Lymphoma

ADCETRIS (brentuximab vedotin) is indicated for treatment of patients with Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates.

This indication is approved under accelerated approval based on overall response rate [see Clinical Studies ( 14.1 ) ].  An improvement in patient-reported outcomes or survival has not been established.  Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Systemic Anaplastic Large Cell Lymphoma

ADCETRIS is indicated for treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen.

This indication is approved under accelerated approval based on overall response rate [see Clinical Studies ( 14.2 ) ].  An improvement in patient-reported outcomes or survival has not been established.  Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

DOSAGE AND ADMINISTRATION

Dosage Recommendations

Administer ADCETRIS as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.  See Table 1 for the recommended starting dosage.

Table 1: Recommended ADCETRIS Dosage
  Recommended Starting Dosage
Normal renal and hepatic function 1.8 mg/kg up to 180 mg
Renal impairment
       Mild (creatinine clearance >50–80 mL/min)
       or moderate (creatinine clearance 30–50 mL/min)
1.8 mg/kg up to 180 mg
       Severe (creatinine clearance less than 30 mL/min) Avoid use
[see Warnings and Precautions ( 5.6 ) ]
Hepatic impairment
       Mild (Child-Pugh A) 1.2 mg/kg up to 120 mg
       Moderate (Child-Pugh B) or severe (Child-Pugh C) Avoid use
[see Warnings and Precautions ( 5.7 ) ]

Dose Modification

Peripheral Neuropathy:  For new or worsening Grade 2 or 3 neuropathy, dosing should be held until neuropathy improves to Grade 1 or baseline and then restarted at 1.2 mg/kg.  For Grade 4 peripheral neuropathy, ADCETRIS should be discontinued.

Neutropenia:  The dose of ADCETRIS should be held for Grade 3 or 4 neutropenia until resolution to baseline or Grade 2 or lower.  Consider G-CSF prophylaxis for subsequent cycles in patients who experience Grade 3 or 4 neutropenia in the previous cycleIn patients with recurrent Grade 4 neutropenia despite the use of G-CSF prophylaxis, consider discontinuation or dose reduction of ADCETRIS to1.2 mg/kg.

Instructions for Preparation and Administration

Administration

  • Administer ADCETRIS as an intravenous infusion only.
  • Do not mix ADCETRIS with, or administer as an infusion with, other medicinal products.

Reconstitution

  • Follow procedures for proper handling and disposal of anticancer drugs [see References ( 15 ) ].
  • Use appropriate aseptic technique for reconstitution and preparation of dosing solutions.
  • Determine the number of 50 mg vials needed based on the patient’s weight and the prescribed dose [see Dosage and Administration ( 2.1 ) ].
  • Reconstitute each 50 mg vial of ADCETRIS with 10.5 mL of Sterile Water for Injection, USP, to yield a single-use solution containing 5 mg/mL brentuximab vedotin.
  • Direct the stream toward the wall of vial and not directly at the cake or powder.
  • Gently swirl the vial to aid dissolution.  DO NOT SHAKE.
  • Inspect the reconstituted solution for particulates and discoloration.  The reconstituted solution should be clear to slightly opalescent, colorless, and free of visible particulates.
  • Following reconstitution, dilute immediately into an infusion bag.  If not diluted immediately, store the solution at 2–8°C (36–46°F) and use within 24 hours of reconstitution.  DO NOT FREEZE.
  • Discard any unused portion left in the vial.

Dilution

  • Calculate the required volume of 5 mg/mL reconstituted ADCETRIS solution needed.
  • Withdraw this amount from the vial and immediately add it to an infusion bag containing a minimum volume of 100 mL of 0.9% Sodium Chloride Injection, 5% Dextrose Injection or Lactated Ringer's Injection to achieve a final concentration of 0.4 mg/mL to 1.8 mg/mL brentuximab vedotin.
  • Gently invert the bag to mix the solution.
  • Following dilution, infuse the ADCETRIS solution immediately.  If not used immediately, store the solution at 2–8°C (36–46°F) and use within 24 hours of reconstitution.  DO NOT FREEZE.

DOSAGE FORMS AND STRENGTHS

For injection: 50 mg of brentuximab vedotin as a sterile, white to off-white lyophilized, preservative-free cake or powder in a single-use vial for reconstitution.

HOW SUPPLIED/STORAGE AND HANDLING

How Supplied

ADCETRIS (brentuximab vedotin) for Injection is supplied as a sterile, white to off-white preservative-free lyophilized cake or powder in individually-boxed single-use vials:

  • NDC (51144-050-01), 50 mg brentuximab vedotin.

Storage

Store vial at 2–8°C (36–46°F) in the original carton to protect from light.

Special Handling

ADCETRIS is an antineoplastic product.  Follow special handling and disposal procedures1.

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017